Literature DB >> 10224836

Epidemiological study of human salmonellosis during 1991-1996 in southern Taiwan.

Y H Chen1, T P Chen, J J Tsai, K P Hwang, P L Lu, H H Cheng, C F Peng.   

Abstract

Within a 6-year period from January 1991 to December 1996, 249 patients of salmonellosis admitted to Kaohsiung Medical College Hospital were enrolled for clinical and microbiological analysis. The number of patients increased by year from 1991 (14 patients) to 1996 (79 patients), especially in the case of nontyphoid salmonellosis. There were 57 different serotypes isolated during these period. Salmonella typhimurium was the most common clinical serotype of human origin in southern Taiwan, followed by S. choleraesuis, S. schwanzengrund, and S. derby. Fever (81.1%), diarrhea (68.9%), and anorexia (44.6%) were the most common manifestations of human salmonellosis. Relative bradycardia was a more important feature in S. typhi group (100%) than nontyphoid salmonellosis. Leukocytosis, especially lymphocytosis, was found especially in nontyphoid, but not in typhoid salmonellosis. Elevated liver function tests were found in the most severe patients, such as S. choleraesuis and S. typhi infections. Malignancy (8.8%), especially hematological malignancy (5.2%), gastrointestinal diseases (8.8%), and diabetes mellitus (6.4%) were the common underlying diseases. Case fatality rate of human salmonellosis was 8% (20/249), especially high in S. choleraesuis group. The severity of underlying diseases may be the major cause in S. choleraesuis group. There was no fatal case with typhoid fever. Very high resistance rate to commonly used antimicrobial agents in nontyphoid Salmonella was noted in southern Taiwan with overall rates of resistance to ampicillin, 67.9%, chloramphenicol, 66.7%, and TMP/SMZ, 42.2%. The emergence of ciprofloxacin-resistant and multiresistant strains was also a major therapeutic problem in this study.

Entities:  

Mesh:

Year:  1999        PMID: 10224836

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

1.  Epidemiologic relationship between fluoroquinolone-resistant Salmonella enterica Serovar Choleraesuis strains isolated from humans and pigs in Taiwan (1997 to 2002).

Authors:  Chao-Chin Chang; Yi-Hsuan Lin; Chao-Fu Chang; Kuang-Sheng Yeh; Cheng-Hsun Chiu; Chishih Chu; Maw-Sheng Chien; Yuan-Man Hsu; Li-Shu Tsai; Chien-Shun Chiou
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

Review 2.  Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease, and treatment.

Authors:  Cheng-Hsun Chiu; Lin-Hui Su; Chishih Chu
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Fluoroquinolone resistance in Salmonella enterica serotype Choleraesuis, Taiwan, 2000-2003.

Authors:  Cheng-Hsun Chiu; Tsu-Lan Wu; Lin-Hui Su; Jien-Wei Liu; Chishih Chu
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

4.  Antimicrobial Resistance and Molecular Investigation of H2S-Negative Salmonella enterica subsp. enterica serovar Choleraesuis Isolates in China.

Authors:  Jing Xie; Shengjie Yi; Jiangong Zhu; Peng Li; Beibei Liang; Hao Li; Xiaoxia Yang; Ligui Wang; Rongzhang Hao; Leili Jia; Zhihao Wu; Shaofu Qiu; Hongbin Song
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  An association of genotypes and antimicrobial resistance patterns among Salmonella isolates from pigs and humans in Taiwan.

Authors:  Hung-Chih Kuo; Tsai-Ling Lauderdale; Dan-Yuan Lo; Chiou-Lin Chen; Pei-Chen Chen; Shiu-Yun Liang; Jung-Che Kuo; Ying-Shu Liao; Chun-Hsing Liao; Chi-Sen Tsao; Chien-Shun Chiou
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

6.  Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan.

Authors:  Jing-Jou Yan; Wen-Chien Ko; Cheng-Hsun Chiu; Shu-Huei Tsai; Hsiu-Mei Wu; Jiunn-Jong Wu
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.